0752 GMT October 19, 2017
The manufacturer, Europe's second-biggest carmaker after Volkswagen, has pledged to drive sales in emerging markets to reduce its reliance on its home region, while reshuffling its three brands to focus on more profitable models, Reuters reported.
PSA's global sales rose to 3.146 million vehicles in 2016 from 2.973 million the previous year, the Paris-based company said in a statement on Wednesday.
The 2016 sales growth represents PSA's best yearly performance since 2010, making it cross the three-million-vehicle threshold for the first time since 2011.
Sales rose 3.56 percent in Europe, which represented about 61 percent of its total deliveries in 2016, compared to about 63 percent a year earlier.
PSA's deliveries surged 112.8 percent — by more than 200,000 units — in the Middle East and Africa region as the Peugeot brand benefited from the lifting of international sanctions on Iran.
However, sales dropped by around 16 percent in China and southeast Asia, where a pricing war led PSA to restructure its activities to reduce costs.
Among PSA's three car brands, Peugeot was the only one to see its deliveries grow in 2016, helped by the launch of revamped versions of its 3008 and 4008 sport-utility vehicles.
The Citroen brand, which is attempting to reposition itself between PSA's upscale DS brand and Peugeot's more mainstream appeal, reported a sales drop of 1.72 percent last year, to 1.141 million units.
"2016 was the year where we were at the lowest point in term of our product cycle," Linda Jackson, Citroen's chief executive told Reuters.
"When we introduced the new C3 — the best-seller for Citroen — at the end of 2016, we started to see the volumes increase," she said, adding she expected to see the brand's volumes advance by 'more than one percent' this year.
Under its so-called 'Push to Pass' strategic plan, PSA is targeting a 30 percent sales increase for the Citroen brand by 2021 versus 2015, to 1.6 million units.
The French carmaker also sees its group revenue increasing by 10 percent by 2018 compared with 2015.